Provided by Tiger Fintech (Singapore) Pte. Ltd.

INmune Bio Inc

2.56
+0.14005.79%
Post-market: 2.53-0.0300-1.17%19:46 EDT
Volume:1.00M
Turnover:2.56M
Market Cap:68.06M
PE:-1.02
High:2.61
Open:2.44
Low:2.43
Close:2.42
52wk High:11.64
52wk Low:1.89
Shares:26.59M
Float Shares:20.18M
Volume Ratio:0.95
T/O Rate:4.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5162
EPS(LYR):-2.1100
ROE:-168.34%
ROA:-55.08%
PB:2.36
PE(LYR):-1.21

Loading ...

Inmune Bio (INMB) Receives a Sell from Scotiabank

TIPRANKS
·
Jul 30

INmune Bio announces video detailing findings from Phase 2 MINDFuL trial

TIPRANKS
·
Jul 29

INmune Bio Inc. Unveils Promising MINDFuL Trial Results for Alzheimer's Treatment XPro™ at AAIC 2025

Reuters
·
Jul 29

INmune Bio Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
Jul 28

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

GlobeNewswire
·
Jul 24

Inmune Bio (INMB) was downgraded to a Sell Rating at Scotiabank

TIPRANKS
·
Jul 05

INmune Bio price target lowered to $7 from $20 at Alliance Global Partners

TIPRANKS
·
Jul 03

INmune Bio Is Maintained at Buy by Maxim Group

Dow Jones
·
Jul 03

INmune Bio price target lowered to $8 from $30 at Maxim

TIPRANKS
·
Jul 02

INmune Bio Shares Fall After Downgrade From BTIG Research

MT Newswires Live
·
Jul 02

INmune Bio Cut to Sector Underperform From Sector Outperform by Scotiabank

Dow Jones
·
Jul 01

BTIG Research Downgrades INmune Bio to Neutral From Buy

MT Newswires Live
·
Jul 01

INmune Bio downgraded to Underperform from Outperform at Scotiabank

TIPRANKS
·
Jul 01

BUZZ-Scotiabank double downgrades rating on INmune Bio after Alzheimer's drug failure

Reuters
·
Jul 01

INmune Bio downgraded to Neutral from Buy at BTIG

TIPRANKS
·
Jul 01

BTIG Reaffirms Their Hold Rating on Inmune Bio (INMB)

TIPRANKS
·
Jul 01

INmune Bio Inc. Closes $19 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Reuters
·
Jul 01

Raymond James Downgrades INmune Bio to Market Perform From Outperform; Shares Fall

MT Newswires Live
·
Jul 01

Biotech INmune BIO (INMB) Collapses 60% after Alzheimer’s Trial Misses Goals

TIPRANKS
·
Jun 30

Top Premarket Decliners

MT Newswires Live
·
Jun 30